Results 1 to 10 of about 50,700 (273)

Pharmacokinetics, Safety, and Efficacy of Intravitreal Digoxin in Preclinical Models for Retinoblastoma [PDF]

open access: yes, 2015
PURPOSE:To assess in vitro cytotoxic activity and antiangiogenic effect, ocular and systemic disposition, and toxicity of digoxin in rabbits after intravitreal injection as a potential candidate for retinoblastoma treatment.METHODS:A panel of two ...
Abramson, David   +13 more
core   +2 more sources

Six months follow up of a single intravitreal injection of ocriplasmin for symptomatic vitreomacular adhesion [PDF]

open access: yes, 2016
Purpose: To evaluate the efficacy and the safety of the enzymatic vitreolysis with a single intravitreal injection of ocriplasmin 125 μg across a group of patients with symptomatic vitreomacular adhesion (sVMA) during 6 months follow up.
GUZZO, Anna Santa   +6 more
core   +2 more sources

Ocular safety of repeated intravitreal injections of Carboplatin and Digoxin: A preclinical study on the healthy rabbits

open access: yesPharmacology Research & Perspectives, 2021
To evaluate the ocular safety of intravitreal carboplatin and digoxin injections as a new intravitreal chemotherapy option for retinoblastoma tumor vitreous seeds. Eighteen rabbits were divided randomly into three groups to receive intravitreal injection
Alireza Khodabande   +6 more
doaj   +1 more source

Intracameral Injection of Bevacizumab for the Treatment of Neovascular Glaucoma [PDF]

open access: yes, 2011
Purpose: To assess the duration of the effect of intracameral bevacizumab in patients presenting with rubeosis iridis and neovascular glaucoma (NVG). Methods: Retrospective analysis of 24 consecutive eyes of 24 patients with decompensated NVG (> 21 mm Hg)
Haritoglou, Christos   +3 more
core   +1 more source

Intravitreal injections, antibiotics and endophthalmitis [PDF]

open access: yesEye, 2013
Sir, The article by Lyall et al1 entitled ‘Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes' is timely, given current efforts to minimize the risk of endophthalmitis following intravitreal injections.
A R, Bhavsar, D R, Sandler, R C, Gentile
openaire   +2 more sources

Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report [PDF]

open access: yes, 2016
Background Ozurdex is a 700 mcg dexamethasone intravitreal implant, approved for the management of macular edema secondary to retinal vein occlusion, and other related pathoglogiesAnterior chamber dislocation of Ozurdex represents an uncommon ...
AGOSTINELLI, Enzo   +6 more
core   +1 more source

Comparison between “early” or “late” intravitreal injection of dexamethasone implant in branch (BRVO) or central (CRVO) retinal vein occlusion: six months follow-up [PDF]

open access: yes, 2017
AIM: The aim of this study was to compare early and late injections of intravitreal dexamethasone implant in patients affected by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with a six-months follow-up.
AUTOLITANO, MONICA   +6 more
core   +1 more source

Widening use of dexamethasone implant for the treatment of macular edema [PDF]

open access: yes, 2017
Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T.   +9 more
core   +2 more sources

Intravitreal injection of ranibizumab for chronic central serous chorioretinopathy

open access: yesJournal of the Egyptian Ophthalmological Society, 2015
Aim The aim of this study was to evaluate the efficacy of intravitreal injection of ranibizumab for patients with chronic central serous chorioretinopathy (CCSC).
Amr Abdel-Fattah Ali Gab-Alla
doaj   +1 more source

Adverse events associated with intraocular injection of anti-VEGF(bevacizumab) in retinal vein ccclusion: a case report [PDF]

open access: yes, 2015
Introduction: Antiangiogenic agents are often administered for treatment of Branch Retinal Vein Occlusion (BRVO). Among them, Bevacizumab has noticeable antiangiogenic and antiedemigenic properties and possesses great capacity to penetrate the retinal ...
ARTICO, Marco   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy